PharmaEssentia looks to broaden focus with checkpoint blocker deal

9 October 2023
biotech_lab_research_vials_medical_big

Taiwanese biotech company PharmaEssentia (TPEx: 6446) has entered into a license agreement with the Irish business of WuXi Biologics (2269. HK) for a new immune checkpoint inhibitor.

PharmaEssentia, a company focused on developing new biologics in hematology and oncology, has bought global exclusive rights to research, develop, manufacture and commercialize the myeloid-targeting candidate.

It is a time of considerable change for the Taipei-based firm, as new approvals for its Besremi (ropeginterferon alpha-2b) are secured,  starting with the US Food and Drug Administration in 2021.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology